Last reviewed · How we verify
NCT06779019: BEST
a Prospective Study of Surgical Results, Complications and Predictive Values in Chinese Women Breast Reconstruction
trial testing LSCI in Breast Reconstruction in 40 participants. Completed in 1 July 2024.
1 July 2024
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 September 2022 |
| Primary completion | 1 July 2024 |
| Estimated completion | 1 July 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- LSCI
- ICG (Indocyanine Green) — full drug profile →
Conditions studied
- Breast Reconstruction — all drugs for Breast Reconstruction →
- Flap Necrosis — all drugs for Flap Necrosis →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 70, female only, with Breast Reconstruction or Flap Necrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study prospectively evaluates and compares the effectiveness of ICG fluorescence imaging and LSCI in predicting the risk of necrosis following direct-to-implant breast reconstruction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06779019
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LSCI
Trials testing the same drug.
- NCT05843929 — Prevalence of the Appearance of Diabetic Ulcers in Patients With 3D Insole and LSCI. · NA · unknown
Other recruiting trials for Breast Reconstruction
Currently open trials in the same condition.
- NCT07230535 — Evaluation of Wellbeing and Patient Reported Outcomes After Open vs Robotic Mastectomy With DIEP Reconstruction · NA · recruiting
- NCT07293052 — Comparison of Outcome Between Grisotti Flap Versus Reverse Mirror Grisotti Flap for Central Quadrant Breast Tumors · NA · active not recruiting
- NCT07331753 — The Outcomes of Fat Grafting Combined With Latissimus Dorsi Muscle Flap for Delayed Breast Reconstruction After Mastecto · NA · recruiting
- NCT07185334 — Single-Stage Prepectoral Placement of Textured Implants Using a Polyester Mesh Endoprostheses With Fluoropolymer Coating · NA · active not recruiting
- NCT06993714 — 3D-printed Biodegradable Breast Implants for Breast Restoration · Phase 2 · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06779019 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 16 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06779019.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing